PH26382A - Radioiodine benzodiazepine derivatives - Google Patents
Radioiodine benzodiazepine derivatives Download PDFInfo
- Publication number
- PH26382A PH26382A PH39046A PH39046A PH26382A PH 26382 A PH26382 A PH 26382A PH 39046 A PH39046 A PH 39046A PH 39046 A PH39046 A PH 39046A PH 26382 A PH26382 A PH 26382A
- Authority
- PH
- Philippines
- Prior art keywords
- formula
- compound
- brain
- benzodiazepine
- iodine
- Prior art date
Links
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 title abstract 2
- -1 Radioiodine benzodiazepine derivatives Chemical class 0.000 title description 3
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 30
- 210000004556 brain Anatomy 0.000 claims description 17
- 229910052740 iodine Inorganic materials 0.000 claims description 12
- 230000002285 radioactive effect Effects 0.000 claims description 12
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 11
- 239000011630 iodine Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical group [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 claims description 6
- 238000003384 imaging method Methods 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 abstract 1
- 238000002610 neuroimaging Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002372 labelling Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229940049706 benzodiazepine Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229940093499 ethyl acetate Drugs 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- FPULFENIJDPZBX-UHFFFAOYSA-N ethyl 2-isocyanoacetate Chemical compound CCOC(=O)C[N+]#[C-] FPULFENIJDPZBX-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ILVUABTVETXVMV-UHFFFAOYSA-N hydron;bromide;iodide Chemical compound Br.I ILVUABTVETXVMV-UHFFFAOYSA-N 0.000 description 2
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- GYVGXEWAOAAJEU-UHFFFAOYSA-N n,n,4-trimethylaniline Chemical compound CN(C)C1=CC=C(C)C=C1 GYVGXEWAOAAJEU-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- FXAXGHCUXZNILI-UHFFFAOYSA-N 6-bromo-4-methyl-1,3-dihydro-1,4-benzodiazepine-2,5-dione Chemical compound O=C1N(C)CC(=O)NC2=CC=CC(Br)=C21 FXAXGHCUXZNILI-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- BVJUXXYBIMHHDW-UHFFFAOYSA-N iodane Chemical group I.I BVJUXXYBIMHHDW-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 210000001694 thigh bone Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K51/047—Benzodiazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Medicinal Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Lubricants (AREA)
- Vessels And Coating Films For Discharge Lamps (AREA)
- Particle Accelerators (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22906488A | 1988-08-05 | 1988-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH26382A true PH26382A (en) | 1992-06-01 |
Family
ID=22859710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH39046A PH26382A (en) | 1988-08-05 | 1989-08-03 | Radioiodine benzodiazepine derivatives |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0353754B1 (xx) |
| JP (1) | JPH0733387B2 (xx) |
| KR (1) | KR930001406B1 (xx) |
| AT (1) | ATE82851T1 (xx) |
| AU (1) | AU622206B2 (xx) |
| CA (1) | CA1318668C (xx) |
| DE (1) | DE58902867D1 (xx) |
| DK (1) | DK381989A (xx) |
| ES (1) | ES2052837T3 (xx) |
| HK (1) | HK127694A (xx) |
| NZ (1) | NZ230193A (xx) |
| PH (1) | PH26382A (xx) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI101305B (fi) * | 1996-03-18 | 1998-05-29 | Map Medical Technologies Oy | Radiofarmaseuttisena aineena käyttökelpoiset radiojodatut bentsodiatse piini-johdannaiset ja niiden käyttö diagnostiikassa |
| WO2005092395A1 (ja) * | 2004-03-25 | 2005-10-06 | Nihon Medi-Physics Co., Ltd. | 放射性組成物及び放射性組成物の製造方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1143728A (en) * | 1979-10-04 | 1983-03-29 | Max Gerecke | Imidazodiazepine derivatives |
| CA1184175A (en) * | 1981-02-27 | 1985-03-19 | Walter Hunkeler | Imidazodiazepines |
| US4352817A (en) * | 1981-02-27 | 1982-10-05 | Hoffmann-La Roche Inc. | Imidazo-diazepines and their use |
| CA1174673A (en) * | 1981-02-27 | 1984-09-18 | Walter Hunkeler | Imidazodiazepines |
| US4777169A (en) * | 1987-07-24 | 1988-10-11 | Hoffmann-La Roche Inc. | Benzodiazepine derivatives |
| JPH0780858B2 (ja) * | 1987-10-19 | 1995-08-30 | 住友化学工業株式会社 | 放射性ベンゾジアゼピン誘導体およびその製造法 |
-
1989
- 1989-08-03 ES ES89114359T patent/ES2052837T3/es not_active Expired - Lifetime
- 1989-08-03 AT AT89114359T patent/ATE82851T1/de not_active IP Right Cessation
- 1989-08-03 PH PH39046A patent/PH26382A/en unknown
- 1989-08-03 NZ NZ230193A patent/NZ230193A/en unknown
- 1989-08-03 EP EP89114359A patent/EP0353754B1/de not_active Expired - Lifetime
- 1989-08-03 DK DK381989A patent/DK381989A/da not_active Application Discontinuation
- 1989-08-03 DE DE8989114359T patent/DE58902867D1/de not_active Expired - Fee Related
- 1989-08-03 CA CA000607447A patent/CA1318668C/en not_active Expired - Fee Related
- 1989-08-04 KR KR1019890011140A patent/KR930001406B1/ko not_active IP Right Cessation
- 1989-08-04 AU AU39342/89A patent/AU622206B2/en not_active Ceased
- 1989-08-04 JP JP1202704A patent/JPH0733387B2/ja not_active Expired - Lifetime
-
1994
- 1994-11-17 HK HK127694A patent/HK127694A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA1318668C (en) | 1993-06-01 |
| KR930001406B1 (ko) | 1993-02-27 |
| AU622206B2 (en) | 1992-04-02 |
| JPH0733387B2 (ja) | 1995-04-12 |
| NZ230193A (en) | 1992-01-29 |
| EP0353754A2 (de) | 1990-02-07 |
| DK381989A (da) | 1990-02-06 |
| EP0353754B1 (de) | 1992-12-02 |
| JPH0269479A (ja) | 1990-03-08 |
| ATE82851T1 (de) | 1992-12-15 |
| AU3934289A (en) | 1990-02-08 |
| DK381989D0 (da) | 1989-08-03 |
| HK127694A (en) | 1994-11-25 |
| EP0353754A3 (en) | 1990-04-11 |
| KR900003171A (ko) | 1990-03-23 |
| DE58902867D1 (de) | 1993-01-14 |
| ES2052837T3 (es) | 1994-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK175089B1 (da) | Estersubstituerede diamindithioler eller farmaceutisek egnede salte deraf, især i steril, farmaceutisk acceptabel form, samt deres anvendelse i forbindelse med radionuclidkomplekser | |
| US4746505A (en) | Technetium radiodiagnostic fatty acids derived from bisamide bisthiol ligands | |
| KR100451077B1 (ko) | 도파민및세로토닌수송체리간드및영상화제 | |
| EP1824830B1 (en) | Radiolabelled quinoline-based ligands for the 5-ht6 receptor functionality | |
| EP0181055B1 (en) | Bis-dimethoxymethyl (trimethoxybenzyl)isoquinolinium salts, their preparation and pharmaceutical compositions containing them | |
| WO2007094718A1 (en) | Radioligands for the 5 -ht1b receptor | |
| WO2003060523A1 (en) | Imaging agents and methods of imaging naaladase of psma | |
| WO1992005154A1 (en) | Novel nitrogen-sulfur ligands useful in radiographic imaging agents | |
| US5986074A (en) | Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof | |
| US4584187A (en) | Imaging agent and method of use | |
| EP1099693A1 (en) | Radiolabelled peptide compounds | |
| WO2006083424A2 (en) | Radiolabeled compounds and uses thereof | |
| KR101469275B1 (ko) | 베타아밀로이드 침착의 영상화를 위한 헤테로사이클릭 인덴계열의 유도체 및 그의 방사성 동위원소 표지화합물 | |
| US20090142264A1 (en) | 18F-Labeled Phenoxyphenyl Nu-benzyl Alkanamid Derivatives for Positron Emission Tomography (PET) Imaging of Peripheral Benzodiazepine Receptor | |
| JP5085824B2 (ja) | 低酸素の検出のために有用な化合物の製造 | |
| CA1318668C (en) | Radioiodine benzodiazepine derivatives | |
| CN112933253A (zh) | 一种放射性核素标记fapi的化合物及其合成工艺方法 | |
| US5096695A (en) | Radioiodine benzodiazepines as brain imaging agents | |
| US20100034741A1 (en) | Imaging agents and methods of imaging alpha7-nicotinic cholinergic receptor | |
| Mathews et al. | Carbon‐11 labeling of a potent, nonpeptide, at1‐selective angiotensin‐II receptor antagonist: MK‐996 | |
| WO1997034898A1 (en) | Process for producing radiolabelled benzodiazepine receptor agents and composition containing the same | |
| CN101486707B (zh) | 亲乏氧肿瘤的硝基咪唑类配合物及其制备方法和应用 | |
| CN101486708B (zh) | 一类锝-99m标记的肿瘤乏氧显像剂及其制备方法和应用 | |
| USH1209H (en) | No-carrier-added (18F)-N-methylspiroperidol | |
| Kassiou et al. | Radiosynthesis of (±)‐1‐(2‐bromo‐4, 5‐dimethoxybenzyl)‐7‐hydroxy‐6‐methoxy‐2‐[11C]‐methyI‐l, 2, 3, 4‐tetrahydro‐isoquinoline,[11C] A‐69024: A non‐benzazepine antagonist for studying dopamine D1 receptors In vivo using PET |